Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

All-Trans Retinoic Acid and Cemiplimab for the Treatment of Patients with Metastatic or Locally Advanced, Unresectable Leiomyosarcoma

Trial Status: active

This phase II trial tests how well giving all-trans retinoic acid (ATRA) and cemiplimab works for the treatment of patients with leiomyosarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (locally advanced) and that cannot be removed by surgery (unresectable). Tretinoin, also called all-trans retinoic acid, ATRA, retinoic acid, and vitamin A acid is in a class of medications called retinoids. It is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. Laboratory made form of tretinoin works by slowing or stopping the growth of cancer cells by causing immature blood cells to develop into normal blood cells. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ATRA and cemiplimab may kill more tumor cells in patients with metastatic or locally advanced and unresectabe leiomyosarcoma.